Here's yet another example of why big pharma can't do biotech - they keep sacking the scientists needed to develop drugs. I've lost count of the amount of times we see this.
http://www.fiercebiotech.com/story/merck-shutter-cubist-site-may-axing-128-staffers/2015-03-06
No surprise if we see Merck in a couple of years offloading remaining Cubist IP & programs they couldn't take further, for a biotech to buy cheaply, take it up to PIII then sell value added back to Merck.
Merck's CEO is a lawyer, not an ex soft drink Co. boss. Either way, still not much use to say a brilliant young upcoming biotech scientist looking for some mentorship as he/she goes about developing breakthrough medical drugs.
- Forums
- ASX - By Stock
- BLT
- Arrowhead buys Novartis' RNAi assets
Arrowhead buys Novartis' RNAi assets, page-10
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BLT (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non Executive Director
Simon Kidston
Non Executive Director
SPONSORED BY The Market Online